INTRODUCTION {#Sec1}
============

Neurodevelopmental disorders (NDDs) are a heterogeneous group of conditions that impact brain development and affect various aspects of daily functioning. At least 30% of NDDs are thought to have a genetic basis.^[@CR1]^ Among these disorders, global developmental delay (GDD)---a precursor diagnosis to intellectual disability (ID)---and autism spectrum disorder (ASD) are two entities for which there are guidelines for genetic testing.^[@CR2],[@CR3]^ The 2010 guideline from the American College of Medical Genetics and Genomics (ACMG) suggests that chromosomal microarray (CMA) and fragile X (FXS) testing should be first-tier tests for individuals with unexplained GDD/ID and/or ASD (except for females with ASD and normal cognition, for which FXS testing is not recommended).^[@CR3]^ There are also considerations for single-gene testing of *MECP2* and *PTEN* under certain circumstances,^[@CR2]^ although gene panels are now typically preferred over single-gene testing. These recommendations and practices exist because of the complex genetic heterogeneity underlying NDDs that sometimes makes diagnostic determinations difficult based on history/examination alone.^[@CR4]^ Even when following these guidelines, establishing a diagnosis can require iterative genetic testing. Previous expert guidance on genetic testing for NDDs has advanced testing as standard of care for individuals with NDDs.^[@CR2],[@CR5]^ Such guidelines also predate the rapid uptake of clinical exome sequencing (ES) and therefore ES is not addressed.

Due to the genetic heterogeneity of NDDs, and the current standard of genome-wide CMA as the first-tier test, we focused on ES in comparison with CMA because it also provides a genome-wide assessment. The advent of ES has elucidated monogenic forms of GDD/ID and/or ASD not detectable by CMA, FXS testing, or single-gene sequencing of *MECP2* or *PTEN*.^[@CR4],[@CR6]^ For individuals with GDD/ID, ASD, and/or multiple congenital anomalies (MCAs), the molecular diagnostic yield of CMA is up to 15--20% (ref. ^[@CR5]^), including more recent cohorts.^[@CR7]--[@CR9]^ CMA typically detects only chromosomal copy-number variants (CNVs) and regions of homozygosity, not single-gene disorders^[@CR10]^ (Table [1](#Tab1){ref-type="table"}). Several ES studies have focused on individuals with varying presentations of NDDs and have identified genetic causes in as many as 61% of cases.^[@CR1],[@CR11],[@CR12]^Table 1Types of genetic variants detected and missed by CMA and ESTestTypes of variants detectedTypes of variants missedCMAChromosomal copy-number variants (deletions and duplications) at the level of intragenic exons or largerBalanced chromosomal rearrangementsLow-level mosaicismTrinucleotide repeat expansion disorders (e.g., fragile X syndrome)Single-gene sequence-level variants found by ESESSingle-gene variantsChromosomal copy-number variants (except when specifically included in analysis pipeline)Balanced chromosomal rearrangementsTrinucleotide repeat expansion disordersIntronic/noncoding variantsExon-level deletions/duplicationsExonic variants not captured or covered well by sequencing platform*CMA* chromosomal microarray,*ES* exome sequencing.

Much like CMA, ES is useful for patients with atypical presentations of a genetic disorder, early presentations of a disease for which the classic findings have not appeared, genetic disorders with relatively nonspecific presentations, and multiple genetic conditions. One of the main historical limitations of ES was lack of detection of CNVs (Table [1](#Tab1){ref-type="table"}), though advances in depth-of-sequence coverage analysis and of apparent Mendelian segregation errors can afford detection of CNVs from ES.^[@CR13]^ With these advances, some clinical laboratories have started to incorporate CNV analysis into their ES platforms.

The value of elucidating a molecular diagnosis is that it can change clinical management in a number of important ways for individuals and families affected by a NDD. Several studies have examined the impact of a diagnostic CMA finding, showing that it leads to direct changes in patient care for up to 55% of individuals with a positive result.^[@CR14]--[@CR17]^ Similarly, a diagnosis via ES can impact patient care by initiation of surveillance for disease-related conditions, discontinuation of repeated rounds of investigation and irrelevant surveillance, and referrals for further evaluation of associated medical conditions.^[@CR18]^ Despite the clear benefit of ES from a diagnostic and management standpoint, there are no accepted guidelines for the use of ES in the evaluation of NDDs.

Therefore, our primary objective was to conduct an evidence-based consensus conference to provide recommendations for the use of ES in the diagnostic evaluation of individuals with NDDs.

MATERIALS AND METHODS {#Sec2}
=====================

We conducted a scoping review (no registered review protocol) as the basis for a consensus development conference to summarize the molecular diagnostic yield of ES for NDDs, specifically compared with CMA. For the conference, in addition to the core group of experts who authored this paper, we also invited outside experts on CNV analysis from ES data.

Scoping review {#Sec3}
--------------

For this scoping review, we addressed the following question: Among individuals with NDDs tested by ES, what is the molecular diagnostic yield compared with CMA? We selected articles from PubMed focusing on ES and NDDs. We included studies that involved sequencing of protein-coding regions of Mendelian genes, and excluded studies that were gene panels subsampled from exome data. We defined NDD as GDD, ID, and/or ASD. We searched PubMed with a combination of Medical Subject Headings (MeSH) terms and keywords pertaining to NDDs (i.e., GDD, ID, and/or ASD) and ES, with dates from 1 January 2014 to 29 June 2018 (Table S[1](#MOESM1){ref-type="media"}). Scoping reviews differ from systematic reviews in that their focus is on more broadly defined research questions, charting of themes, and development of inclusion/exclusion criteria at the study selection stage.^[@CR19]^

Article selection occurred in two stages. During the first stage, 12 expert reviewers (representing a diverse range of fields including laboratory genetics, clinical genetics, genetic counseling, developmental behavioral pediatrics, and medical students) were divided into dyads for determination of possible inclusion. Articles included at this stage were primary research studies (e.g., cohort studies, case series with ≥10 participants, review articles, or other articles of interest such as expert opinion). Exclusion criteria were as follows: the article did not (1) include the clinical population of interest, (2) discuss ES, (3) include human data (e.g., an animal or in vitro study only), (4) discuss molecular diagnostic yield, or (5) include ≥10 participants. Each dyad of reviewers was blinded to the other's choices and independently assigned inclusion/exclusion criteria for each article. When a discrepancy occurred, an independent reviewer assessed whether the article should advance to full article review.

During the second stage, a dyad read the full text of each remaining article for possible inclusion to clarify inclusion eligibility. Reasons for exclusion at this stage were tiered by the following criteria: (1) basic science study, (2) study population not exclusively NDD, (3) \<10 participants, (4) did not discuss ES, (5) no mention of molecular diagnostic yield, (6) methods or review paper, or (7) not otherwise defined (book chapter or not in English). We established strict phenotypic NDD guidelines to limit the heterogeneity of included articles. Specifically, when describing the population of interest, the article must have used the phrases "global developmental delay," "intellectual disability," and/or "autism spectrum disorder" (or its equivalent). The term "developmental delay" lacked enough specificity unless there were additional context clues to suggest it was referring to GDD/ID. We classified included articles as belonging to one of two categories: (1) isolated NDD: the study population pertained to NDD; or (2) NDD plus associated conditions: the study population pertained to NDD plus a specific clinical finding (defined as *any* additional neurological, systemic, syndromic, or other clinical characteristic, e.g., microcephaly, neutropenia, or Coffin--Siris syndrome).

We conducted two iterative changes outside of the original scoping review. First, during the conference, members nominated nine additional articles for consideration. Select consensus conference members reviewed the articles' full text and identified one additional article for inclusion that was not ascertained through the MeSH and keyword search terms. Second, although our manual review included "global developmental delay," we modified our MeSH and keyword search terms to include "global developmental delay" and to use "exome sequencing" or "whole exome sequencing" (instead of just "whole exome sequencing"). The same select consensus conference members reviewed all the abstracts of the articles not previously captured by the initial MeSH and keyword search terms, and read a subset of the full-text articles, ultimately identifying one more article for inclusion.

Consensus development conference {#Sec4}
--------------------------------

This effort began as an initiative of the Translational Neuroscience Center (TNC) at Boston Children's Hospital (BCH), following multiple discussions with experts in the field. The idea of investigating whether there was evidence to support use of clinical ES for patients with NDDs was presented to a TNC donor who provided a modest noncommercial unrestricted donation to support travel expenses of working group members to hold an in-person meeting. The core author group from BCH then convened an interdisciplinary group of experts in clinical genetics, laboratory genetics, genetic counseling, child neurology, neurodevelopmental disabilities, and developmental behavioral pediatrics to determine the need for a scoping review on ES in NDDs. We conducted this project outside the scope of professional organizations for two specific reasons: (1) we wanted the group of experts to represent different countries and disciplines, to create diverse perspectives that would minimize bias; and (2) we considered the question of selecting the genetic test with highest diagnostic yield for NDDs to be an urgent issue, and that our approach would be expedient without compromising the validity of conclusions.

This consensus group developed the framework and selected separate experts to conduct the review. Members of the consensus group provided conflicts of interest disclosure in a standard format. Following the scoping review, the consensus group reconvened to review the evidence curated by the expert review group. We assembled this interdisciplinary team based on practice/geographic diversity and assessments of conflicts of interest, and we used a consensus development conference approach.^[@CR20]^ This approach is one of the three main approaches to develop consensus and was chosen for its unique strength of allowing committee members a forum to discuss issues.^[@CR21]^ The committee reviewed the evidence table, discussed talks on relevant topics presented by a variety of members and two external experts from clinical laboratories performing ES, voted on the use of ES as a first-tier test for NDDs, and developed a consensus algorithm for genetic testing, including ES, in NDDs.

Statistical analysis {#Sec5}
--------------------

We assessed fixed-effects and random-effects models for model fit. We performed a random-effects meta-regression to determine molecular diagnostic yield of full sample, and stratified by category (isolated NDD, NDD plus associated conditions). Category, year of study, number of participants with a NDD, and number of family members included per proband were evaluated as covariates. For number of family members included, we created three categories: (1) proband-only (all cases proband-only), (2) combination (all cases *at least* proband), and (3) trio (all cases*at least* trios). Of note, we included two studies in the combination category in which parental samples were obtained post hoc for variant classification.

Meta-regression was performed using a logistic regression model. Between-study heterogeneity was assessed using between-study variance (τ^2^), I-2 statistic, and Cochran's Q-test. Akaike information criterion and Bayesian information criterion were assessed to evaluate model fit. A forest plot was used to summarize our findings.

RESULTS {#Sec6}
=======

For the scoping review staged selection process, we initially identified 584 unique articles. We eliminated 464 articles after abstract review, and another 92 after full-text review, leaving 28 articles for inclusion. During the iterative review, we identified 389 unique articles, eliminated 378 after abstract review, and another 9 after full-text review, leaving 2 for inclusion. In total, 30 articles were included, which we divided into two categories: those focused on just NDDs or those focused on NDDs plus associated conditions. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1**Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of scoping review article inclusion.** ^a^Records identified through iterative review were reviewed by one reviewer at the screening stage.*ES* exome sequencing,*NDD* neurodevelopmental disorder.

The 30 articles (Table S[2](#MOESM2){ref-type="media"}) were diverse in their patient representations. These articles originated from centers around the world, including the United States, Europe, Middle East, and Asia. Among the articles focused on NDD plus associated conditions, the features included features of a clinically defined syndrome (e.g., Coffin--Siris syndrome, DOOR syndrome, Nicolaides--Baraitser syndromes, Rett syndrome, Smith--Magenis syndrome); systemic findings (unexplained metabolic phenotype); associated medical problems (neutropenia); and neurological features (microcephaly, macrocephaly). The types of specialists evaluating the phenotypes of participants represented a diverse variety including clinical geneticists, pediatric neurologists, and developmental pediatricians.

A random-effects meta-analysis of the 30 articles revealed a molecular diagnostic yield of ES of 36% (confidence interval \[CI\]: 30--43%) weighted by the number of cases in the study (Fig. [2](#Fig2){ref-type="fig"}). In the isolated NDD category (*n* = 21 articles), the yield was 31% (CI: 25--38%), and in the NDD plus associated conditions category (*n* = 9 articles), the yield was 53% (CI: 41--64%).Fig. 2**Forest plot of meta-analysis subcategorized as neurodevelopmental disorder (NDD) and NDD plus associated conditions.***CI* confidence interval.

Within both the isolated NDD category and the NDD plus associated conditions category, patterns emerged pertaining to molecular diagnostic yield. Among the articles pertaining to the isolated NDD category, there were *n* = 5 articles including individuals with primarily ASD (molecular diagnostic yield 16%, CI: 11--24%), *n* = 10 articles that included individuals with primarily ID (yield 39%, CI: 29--50%), *n* = 6 articles that included individuals with a more heterogeneous mix of ID and/or ASD (yield: 39% (CI: 29%--50%)), and *n* = 4 articles focused on mostly consanguineous populations (yield: 29%, CI: 23--35%). Meta-regression revealed that year of study, number of family members sequenced, and isolated NDD versus NDD plus associated conditions category did not significantly predict molecular diagnostic yield.

Several studies (*n* = 6) showed that a presumptive diagnosis by ES could change clinical management (Table S[2](#MOESM2){ref-type="media"}). Among those with a diagnosis by ES, changes in medical/medication management occurred in 30% (range: 2--46%; *n* = 6 studies). Four studies discussed impact on reproductive planning and found that 80% (range: 42--100%) of diagnoses were informative for reproductive planning. For those for whom the diagnosis was not informative for reproductive planning, the reasons were not entirely clear. Of note, these numbers on clinical management impact are not necessarily specific to individuals with NDD, since for some studies, we used a subset of the study population to calculate molecular diagnostic yield for NDDs.

DISCUSSION {#Sec7}
==========

Our scoping review revealed that, among patients with NDDs, ES outperforms the currently accepted first-tier test for NDDs by 10--28%, assuming a range of 30--43% for ES and 15--20% for CMA. Both of these tests are advantageous as unbiased approaches with genetically heterogeneous conditions like NDDs. However, based on this significantly higher molecular diagnostic yield combined with the fact that a diagnosis often impacts clinical management, we recommend ES (including both parents, when feasible and with multiple affected family member analysis, when indicated) as a first-tier test for individuals with unexplained NDDs (Fig. [3](#Fig3){ref-type="fig"}). In fact, ES has advantages, such as detection of individuals with multiple monogenic disorders, facilitating characterization of blended phenotypes.^[@CR22]^ Multiple prior studies have shown that results from ES impact clinical management for NDDs and other conditions,^[@CR18],[@CR23]^ which our results support.Fig. 3**Diagnostic algorithm incorporating exome sequencing (ES) in the clinical evaluation of individuals with unexplained neurodevelopmental disorders (NDDs) (global developmental delay/intellectual disability \[GDD/ID\] and/or autism spectrum disorder \[ASD\]).** An incomplete diagnosis represents a diagnosis that explains only part of an individual's phenotype. Factors such as the turnaround time of test, availability of tests, and availability of genetic counseling may be considerations in application of this algorithm in clinical use. ^a^Or technology that supersedes ES such as genome sequencing. *CMA* chromosomal microarray, *CNV* copy-number variant.

If ES is nondiagnostic, we suggest that the next step in the evaluation is CMA (if not already performed, either standalone or as part of ES analysis). If CMA is nondiagnostic, then the clinician can consider further evaluations/tests, including, but not limited to, referral to a clinical geneticist for expert evaluation; periodic (every 1--3 years) reanalysis of ES data, given evidence that doing so may enhance molecular diagnostic yield by 10--16% (refs. ^[@CR24]--[@CR26]^); FXS testing; metabolic testing and/or mitochondrial DNA (mtDNA) sequencing based on clinical presentation (though some laboratories perform mtDNA analysis with ES); and karyotyping to assess for balanced chromosomal rearrangements.

Our algorithm places ES before, or concurrent with, CMA, as the molecular diagnostic yield of ES for NDDs exceeds that of CMA. Estimates for the molecular diagnostic yield of CMA are 15--20%, but this number includes individuals with MCAs, which we did not include in our inclusion criteria unless there was also the presence of GDD/ID and/or ASD. There are certain additional points that will allow this algorithm to remain meaningful as sequencing technology and bioinformatic analyses continue to improve. First, CNV analysis is typically not a standard application of ES across all labs. As a result, the diagnostic yield of CMA and ES for NDDs is approximately the sum of each respective diagnostic yield (i.e., 15--20% for CMA based on prior literature plus 30--43% for ES in our study). Nonetheless, there is increasing movement toward incorporating CNV calling algorithms into ES analysis pipelines.^[@CR27]^ For example, within the articles included in our scoping review, three studies called CNVs from exome:^[@CR1],[@CR28],[@CR29]^ two reported CNV yields for NDDs of 16.7% (ref. ^[@CR28]^) and 6.4% (ref. ^[@CR29]^), and the latter identified two pathogenic CNVs that were not detected on CMA due to poor coverage.^[@CR29]^ Second, genome sequencing (GS), by definition, captures more comprehensively all classes of genetic variants in testing (Table [1](#Tab1){ref-type="table"}). We anticipate that GS will eventually supersede ES and CMA in clinical testing algorithms over time, as cost decreases.

It is worthwhile to note comparisons between ES and panel testing. Sensitivity for detection of mosaicism can be lower on ES compared with panel testing, for which read depth and sequence coverage is often greater.^[@CR30]^ ES has lower sensitivity to detect single exon--level deletions/duplications, which may be better detected by panels when targeted deletion/duplication analysis is included. However, gene panels require continual curation of a well-defined/comprehensive gene set for phenotypes for which many genes are yet to be discovered.^[@CR31]^ Moreover, panels are fixed in the number of genes originally assessed, while ES allows for reanalysis of the data set.

It is also important to note that a diagnosis from ES should not end with laboratory classification of a variant. For instance, the classification of a variant of unknown significance (VUS) from a laboratory should be further evaluated in the clinical setting. With increased knowledge over time of phenotypes related to different genetic disorders, exome reanalysis may change the clinical interpretation of a VUS. Furthermore, a likely pathogenic variant has approximately a 90% true positive rate, so there is approximately a 10% false positive rate as the cause of an individual's presentation; therefore, clinical judgment is important in establishing a diagnosis.^[@CR32]^ Even pathogenic variants may be incompletely penetrant or only partly explain presenting features. Ultimately, final variant interpretation of the ES test result requires review by expert clinicians who can reassess the patient's phenotype in light of the suggested molecular diagnosis.

Our results demonstrate that the presence of additional clinical features, year of study, and number of family members included in exome analysis did not correlate with molecular diagnostic yield in our meta-regression. Factors such as number of studies pertaining to each of the variables may have contributed to this result, and therefore it still may be the case that the presence of multiple additional phenotypic features may enrich molecular diagnostic yield (as evidenced by the fact there was a higher diagnostic yield in the NDD plus associated conditions category versus the isolated NDD category, though not statistically significant). Additionally, while our findings did not demonstrate higher yield when including more family members, many of the studies were a mixture of proband-only and trio ES, limiting our ability to detect differences in molecular diagnostic yield. Because of this, we expect that the additional yield of trio ES seen in other studies remains true.^[@CR1],[@CR33]^ Our analysis did not account for history of consanguinity in the meta-regression, though this additional factor may enrich molecular diagnostic yield, based on increased probability of autosomal recessive conditions. Additionally, we were not able to determine whether increased ID severity increased molecular diagnostic yield in our regression, but this factor may be another consideration. In sum, ES demonstrates a higher diagnostic yield, relative to CMA, for individuals with NDDs, with/without additional features. This is attributable to the ability of ES to detect the most prevalent types of pathogenic variants affecting this population (single-nucleotide variants \[SNVs\]), and that those SNVs represent many loci. This is not surprising because the phenotypic category of NDDs features a high degree of locus heterogeneity and phenotypic variability.

It is worthwhile to consider who would order ES as a first-line test for NDDs. We suggest that test ordering should not be limited to a particular specialty; rather, it is contingent on the ordering provider's ability to provide informed consent about variant interpretation and secondary findings, and the ability to interpret/report results. Providers should inform patients on possible results, both primary and secondary.^[@CR34]^ We have not included assessments of cost-effectiveness and insurance approval for ES in our evaluation.

Laboratory interpretation standards, case review boards, and reanalysis protocols might also affect yield from exome sequencing.^[@CR24],[@CR26],[@CR35]^ We compared diagnostic yield of ES to CMA, and note that CMA results can also be affected in the same ways.^[@CR36]^ A recent prospective study examined the use of ES for establishing molecular diagnoses in fetal structural anomalies, involving multidisciplinary input that is important when the phenotype is complex.^[@CR37]^

Our analysis had limitations. The scoping review focused on ID and/or ASD, since these are the two NDDs for which there are recommendations already in place for genetic testing. We recognize that our search strategy may have led to exclusion of some articles where phenotype was less specific, such as use of "developmental delay" instead of GDD. For reasons of consistency, we were stricter in our search strategy. Second, we made inferences about the study population in*n* = 9 studies (e.g., presuming "ID/DD" is ID/GDD). Several studies did not formally define the basis for ASD or ID/GDD. Even in studies belonging to the isolated NDD group, the study population was heterogeneous (e.g., ID plus variable other features though not necessarily plus another specific phenotype). Moreover, although our scoping review had selected articles focusing on GDD, it had not been included in our initial MeSH terms, so we repeated our PubMed search with this change. Further, we excluded certain studies with heterogeneous cohorts for which we could not ascertain the number of individuals with NDD. One such study focused on ID *and/or* epileptic encephalopathies,^[@CR38]^ while another such study focused on NDDs (but broadly defined NDD to include a heterogeneous array of neurological symptoms without clear delineation of subset with GDD/ID and/or ASD).^[@CR39]^ Though it may seem surprising that there were more papers on isolated NDD than NDD plus associated conditions, the reason for this is that we only included an article in the NDD plus associated conditions category if *all* participants in that article had NDDs on top of the additional feature(s). In addition, not all studies used the ACMG variant classification guidelines. In part, this was due to the time period of study inclusion, which began in 2014; the ACMG did not release variant classification guidelines until 2015.^[@CR40]^ Another limitation is that we did not include mtDNA sequencing in our analysis. We also recognize that the data were drawn from a variety of both clinical and research settings, and that specific analysis approaches may differ in terms of variant filtering and technical platform (e.g, trio-based ES versus proband-only ES). It is expected that by looking at meta-analysis we account for some of this variability. The second to last limitation is that we acknowledge additional cost analyses associated with the genetic testing technologies will also be important, though these were not part of the original purpose of our study, which focused on molecular diagnostic yield. Finally, while there may be publication bias favoring positive results, this effect is diminished by the large cohorts in our analysis and multiple studies involving consecutively ascertained cases. Publication bias should apply equally to studies on yield of CMA and ES.

Our work establishes that, among patients with NDD, ES produces a higher molecular diagnostic yield than CMA, so by this criterion and as outlined in our algorithm (Fig. [3](#Fig3){ref-type="fig"}), it should become a first-tier test. As our recommended algorithm is adopted, we anticipate numerous additional health and economic impact studies about changes in patient-related outcomes enabled by genome sequence--based diagnosis. While step-wise testing has historically had a role in identifying a genetic diagnosis, simplicity is ideal, and a diagnosis can now be accomplished for many patients in a single test with an already impressively high molecular diagnostic yield. Such clinical diagnostic yields will increase with reannotation of the existing data compared with new data sets and with new computational tools.^[@CR32]^ This report will guide geneticists, neurologists, developmental pediatricians, child psychiatrists, and other clinicians in incorporating clinical exome or genome sequencing into the management of individuals with NDDs.
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**Change history**
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In our meta-analysis, we utilized incorrect numbers of individuals for one publication (Retterer et al., 2016) due to the fact the numbers for ASD and ID groups were not independent representations. We have updated our analysis using corrected numbers based on correspondence with the first author of this paper (diagnostic yield for NDD = 543/1736 as opposed to 570/2063). The updated analysis leads to the same (rounded) weighted diagnostic yield and confidence intervals (CI) as the initial publication (36% \[30%--43%\]). The updated analysis results in the following updated values in Figure 2 \-- Retterer study values: N positive = 543, N total = 1736, study weight = 5.3% and meta-analysis statistics: I2 = 80%, t2 = 0.2835, *p* \< 0.01. The study is also included in two subanalyses reported in the Results. The isolated NDD subcategory (*n* = 21 articles), updated analysis leads to same (rounded) weighted diagnostic yield and confidence intervals as published (31% \[25%--38%\]). For the sub-analysis of mix of ID and/or ASD, the initial yield was 37% (CI: 29%--46%). Following updated analysis, the yield of this subset is 39% (CI: 29%--50%).
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